Enterprise League logo

Service

Amubarvimab/Romlusevimab

BIOTECHNOLOGY

byBrii Biosciences

United States (US)

ABOUT THE SERVICE

Brii Biosciences’ monoclonal antibody combination therapy, BRII-196/BRII-198, is designed to neutralize SARS-CoV-2 and provide a treatment option for non-hospitalized COVID-19 patients at high risk of clinical progression to severe disease. It received approval from the NMPA in China.

Information is owner-confirmed

Last updated Yesterday

Price range
N/A

Other products/services from Brii Biosciences